Grégoire Jean-Baptiste Philippe

Grégoire Jean-Baptiste Philippe

Auto-generated profile, based on publicly available information

Grégoire Jean-Baptiste Philippe

Department of Chemistry, Graduate School of Science, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
GPGrégoire J.B. Philippe
Grégoire J.B. Philippe
DCDavid J. Craik
David J. Craik
SHSonia Troeira Henriques
Sonia Troeira Henriques

10 June 2016 in Peptide Science
Verified
Journal Article
Closed access
PDF file
GPGrégoire Philippe
Grégoire Philippe
YHYen-Hua Huang
Yen-Hua Huang
OCOlivier Cheneval
Olivier Cheneval
NLNicole Lawrence
Nicole Lawrence
ZZZhen Zhang
Zhen Zhang
SHSonia Troeira Henriques
Sonia Troeira Henriques

20 October 2020 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
NLNicole Lawrence
Nicole Lawrence
GPGrégoire J.-B. Philippe
Grégoire J.-B. Philippe
PHPeta Harvey
Peta Harvey
NCNicholas D. Condon
Nicholas D. Condon
ABAurelie Benfield
Aurelie Benfield
SHSonia Troeira Henriques
Sonia Troeira Henriques
Cell penetrating peptides (CPPs) are valuable tools for developing anticancer therapies due to their ability to access intracellular targets, including protein–protein interactions. cPF4PD is a newly described CPP designed from a transduction domain of the human defense protein platelet factor 4 (PF4), that also has antimalarial activity. The cPF4PD peptide recapitulates the helical structure of the PF4 domain and maintains activity against intracellular malaria parasites via a selective membrane-active mechanism. We hypothesized that cPF4PD and PF4-derived peptide analogues would enter cancer cells and have utility as scaffolds for delivering a peptide dual inhibitor (pDI) sequence with ability to inhibit p53:MDM2/X interactions and reactivate the p53 pathway. Here we designed and produced PF4 peptide and PF4 peptide-pDI grafted analogues with low micromolar activity toward melanoma and leukemia. Two grafted analogues achieved a stable helical structure and inhibited interaction with MDM2 and MDMX. These peptides reached the cytoplasm of cells but were unable to reactivate the p53 pathway. Instead, the cytotoxic mechanism was attributed to peptide binding to mitochondrial membranes that perturbed function within two hours of treatment. These studies of PF4-derived CPPs suggest their potential as scaffolds for delivering cell-impermeable cargoes into the cytoplasm of cells and highlight the importance of characterizing the internalization and cell death mechanism of designer peptide-based drugs.

3 February 2021 in ACS Chemical Biology
Verified
Journal Article
Closed access
GPGrégoire J.-B. Philippe
Grégoire J.-B. Philippe
AMAnna Mittermeier
Anna Mittermeier
NLNicole Lawrence
Nicole Lawrence
YHYen-Hua Huang
Yen-Hua Huang
NCNicholas D. Condon
Nicholas D. Condon
SHSonia Troeira Henriques
Sonia Troeira Henriques

4 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GPGrégoire Jean-Baptiste Philippe
Grégoire Jean-Baptiste Philippe
YHYen-Hua Huang
Yen-Hua Huang
AMAnna Mittermeier
Anna Mittermeier
CBChristopher J. Brown
Christopher J. Brown
QKQuentin Kaas
Quentin Kaas
DCDavid Craik
David Craik

25 July 2025 in Australian Journal of Chemistry
Verified
Journal Article
Closed access
SUSven Ullrich
Sven Ullrich
GPGrégoire Jean-Baptiste Philippe
Grégoire Jean-Baptiste Philippe
CLChoi Yi Li
Choi Yi Li
HSHiroaki Suga
Hiroaki Suga
Naturally occurring cyclic peptides have emerged as intriguing and relevant scaffolds for next-generation drug design. Especially peptides from the highly constrained cyclotide family provide an exceptional opportunity for drug discovery, given their characteristic head-to-tail cyclic structure and cystine-knotted core that confer favourable pharmaceutical properties. As a result, Momordica cochinchinensis trypsin inhibitor II (MCoTI-II), a cyclic knottin peptide natural product of gấc fruit, has been the centre of various molecular engineering efforts. To target medicinally relevant proteins, surface-exposed loops of the mini-protein have been purposefully modified or entirely selected de novo to install bioactive epitopes. This mini-review aims to provide a succinct overview of recent studies on MCoTI-II-derived structures in inhibitor and diagnostic design. A variety of methods facilitate access to MCoTI-II-based next-generation therapeutics and diagnostics, including rational design, loop grafting and genetically encoded discovery platforms.